Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.
Actinogen Medical is currently conducting XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in early 2019.
"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."
|14.11.2018||Appendix 3B-Exercise of Options|
|08.11.2018||Supportive research highlights cortisol hypothesis|
|31.10.2018||September 2018 Quarterly Update|
|31.10.2018||Vesting Conditions Met|
|30.10.2018||Actinogen to be showcased at AusBiotech Invest 2018|
|29.10.2018||Enrolment target achieved for major Alzheimer’s trial-XanADu|
|24.10.2018||XanADu trial to be presented at global Alzheimer conference|